Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.